Maitland, Florida
Alzheimer's disease clinical trials in Maitland, FL
19 Alzheimer's disease studies are recruiting participants at sites in Maitland as of November 16, 2026, according to ClinicalTrials.gov. Clinical Trials for Alzheimer's Disease can help you understand your options and connect with a study team.
- No cost to ask
- Taking part is voluntary
- Studies are independently reviewed
Maitland at a glance
- 19 studies are recruiting at a site in Maitland.
- By phase: Phase 1 (4), Phase 1/2 (1), Phase 2 (7), Phase 3 (6), Observational (1).
- By sponsor: industry (19).
- Most recent update to one of these records: November 16, 2026.
Studies recruiting in Maitland
Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Phase 3
- Ages 50 to 90
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- K2 Medical Research, LLC
- Registry record
- NCT07177352 · updated
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- K2 Medical Research - Maitland
- Registry record
- NCT05980949 · updated
A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- Phase 3
- Ages 55 to 80
- All sexes
- Sponsor
- Hoffmann-La Roche
- Study site
- K2 Medical Research, LLC
- Registry record
- NCT07717411 · updated
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
- Phase 2
- Ages 55 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- K2 Medical Research ORLANDO
- Registry record
- NCT07589595 · updated
A Study of LY3439539 in Participants With Alzheimer's Disease
- Phase 1
- Ages 50 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- K2 Medical Research
- Registry record
- NCT07598370 · updated
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease
- Phase 2
- Ages 55 and older
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study site
- K2 Medical Research
- Registry record
- NCT06540833 · updated
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
- Phase 2
- Ages 55 and older
- All sexes
- Sponsor
- Intra-Cellular Therapies, Inc.
- Study sites
- K2 Medical Research · Neurology Associates PA
- Registry record
- NCT06651567 · updated
A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease
- Phase 1
- Ages 50 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- K2 Medical Research, LLC
- Registry record
- NCT06297590 · updated
An Open Label Dose Escalation Study of VY1706 in Participants With Early Alzheimer's Disease
- Phase 1
- Ages 30 to 80
- All sexes
- Sponsor
- Voyager Therapeutics
- Study site
- K2 Medical Research, LLC
- Registry record
- NCT07764146 · updated
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
- Phase 3
- Ages 55 and older
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- K2 Medical Research ORLANDO
- Registry record
- NCT07602582 · updated
[18F]PI-2620 Phase 3 Histopathological Study
- Phase 3
- Ages 50 and older
- All sexes
- Sponsor
- Lantheus Biosciences Ltd.
- Study site
- K2 Medical Research
- Registry record
- NCT05641688 · updated
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
- Phase 2
- Ages 50 to 85
- All sexes
- Sponsor
- Merck Sharp & Dohme LLC
- Study site
- K2 Medical Research ( Site 1047)
- Registry record
- NCT07033494 · updated
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
- Phase 2
- Ages 40 to 55
- All sexes
- Sponsor
- Alnylam Pharmaceuticals
- Registry record
- NCT07636811 · updated
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Phase 2
- Ages 55 to 90
- All sexes
- Sponsor
- Celgene
- Study site
- ClinCloud
- Registry record
- NCT06808984 · updated
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
- Phase 1/2
- Ages 40 to 85
- All sexes
- Sponsor
- NKGen Biotech, Inc.
- Study site
- K2 Medical Research
- Registry record
- NCT06189963 · updated
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
- Phase 3
- Ages 55 to 90
- All sexes
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Study site
- K2 Medical Research - Maitland
- Registry record
- NCT05511363 · updated
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
- Phase 1
- Ages 45 to 85
- All sexes
- Sponsor
- Eli Lilly and Company
- Study site
- K2 Medical Research
- Registry record
- NCT06657768 · updated
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
- Observational
- Ages 60 to 90
- All sexes
- Sponsor
- GAP Innovations, PBC
- Study site
- K2 Medical Research
- Registry record
- NCT06584357 · updated
Open-label Extension Study in Participants With Early Alzheimer's Disease
- Phase 2
- Ages 50 to 85
- All sexes
- Sponsor
- GlaxoSmithKline
- Study site
- GSK Investigational Site
- Registry record
- NCT07105709 · updated
Source: ClinicalTrials.gov. Data processed . See every Alzheimer's disease study recruiting in Maitland, FL on ClinicalTrials.gov.
Ask about studies near Maitland
Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.
Before you contact a study
How taking part works
From your first question to your decision: what happens and who you talk to along the way.
Questions to ask a study team
What to ask about time, risks and your rights before you agree to anything.
Eligibility and screening
How a study team works out whether a study is suitable for you.
More locations in Florida
All Florida locations
61 studies recruiting across 50 cities.
Miami
24 studies recruiting.
Tampa
20 studies recruiting.
Orlando
19 studies recruiting.
Winter Park
11 studies recruiting.
Stuart
10 studies recruiting.
About these listings
These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.
Clinical Trials for Alzheimer's Disease does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.
Sources and further reading
- ClinicalTrials.gov study registry — ClinicalTrials.gov (National Library of Medicine)
- Terms and Conditions for use of ClinicalTrials.gov data — ClinicalTrials.gov (National Library of Medicine)
- Questions to Ask About Volunteering for a Research Study — HHS Office for Human Research Protections